阿尔茨海默病Aβ免疫治疗规范与流程OA

In 2024 anti-β-amyloid(Aβ)monoclonal antibodies(Lecanemab and Donanemab)were approved to enter the market at home and abroad.They are gradually used in clinical practice.In order to promote the more reasonable and safer application of anti-Aβ monoclonal antibodies in the treatment of Alzheimer's disease(AD)in China,this article summarizes the existing clinical trial evidence of anti-Aβ monoclonal antibodies and some experience in the clinical application.The clinical treatment specifications and processes of monoclonal antibodies,including clinical drug indications,pre-medication evaluation and preparation,medical instructions and precautions during medication,and post-medication clinical monitoring,are constructed to build a standardized treatment system for AD,and the plateau adaptability plan is optimized,aiming to provide clinicians with detailed medication guidance and suggestions,and further promote the standardization and precision of AD treatment.